INTRODUCTION
The initiation of blood coagulation and subsequent wound repair is a fundamental defence mechanism conserved in all extant vertebrates [1, 2] . The high blood pressure generated on the arterial side of the vertebrate circulation requires a powerful, almost instantaneous but strictly localized procoagulant, response to minimize blood loss from sites of vascular injury without compromising blood flow. In addition, it interacts with other defence mechanisms, such as the immune system and the inflammatory response. At the heart of this complex network of interacting pathways is the cellular receptor tissue factor (TF).
TISSUE FACTOR: STRUCTURE AND FUNCTION
TF, also known as thromboplastin or factor (F) III, is a 47-kDa type 1 transmembrane glycoprotein that is the cellular receptor and cofactor for blood coagulation factor VII/VIIa (FVII/VIIa). The gene encoding human TF (F3) is located on chromosome 1 (1p22-p21) and spans 12 640 nucleotides and consists of six exons. The 2351 nucleotide mRNA transcript encodes a 295 amino acid primary translation product that is processed to a mature TF protein of 263 amino acids in length after cleavage of the 32 amino acid signal peptide. The 219-residue extracellular region consists of two fibronectin type III domains orientated at an angle of 1258 ( Fig. 1 ) anchored into the cell membrane by a 23-residue transmembrane sequence followed by a 21 amino acid cytoplasmic tail. There are three N-linked glycosylation sites (N43, N156 and N169), two disulfide bridges (C81-C89 and C275-C295), an S-palmitoyl cycteine (C277) and a phosphorylated serine at position 290 [all residues are numbered according to Goodeve et al. [4 & ] using Human Genome Variation Society (HGVS) nomenclature numbering the initiation methionine (þ1) of the reference protein sequence (NP_001984) and may differ from previous publications by legacy numbering þ32]. These potential posttranslational modification sites with the exception of the N-linked glycosylation site N156 are all highly conserved (Fig. 1) .
Systematic site-directed mutagenesis [5] [6] [7] [8] [9] [10] and radiograph crystallographic analysis [11] [12] [13] of TF and TF-FVIIa complexes have identified the KEY POINTS TF is the cellular receptor and cofactor for blood coagulation factor VII/VIIa. Exposure of flowing blood to cells expressing TF is sufficient and necessary to initiate blood coagulation.
TF-initiated thrombin generation leads to cellular signalling through activation of PARs. The accession number (gi) of each sequence is given. Sequences were aligned using Clustal W [3] . The transmembrane domain sequence is boxed. Disulfide bonds are indicated by square brackets. N-linked consensus glycosylation sites are indicated by * . The putative substrate-binding region is indicated by . The percentage identity and similarity of each sequence with the human reference sequence is given. (b) Molecular model of the complex between active site inhibited factor VIIa and the extracellular domain of tissue factor (Protein Databank: 1DAN). Factor VIIa protein chain is represented by a grey ribbon. The active site inhibitor is shown in ball and stick. Calcium ions are represented by red spheres. The tissue factor protein chain is represented by a green ribbon with residues conserved in all species analysed shown in blue. EGF, epidermal growth factor; Gla, g-carboxylated.
molecular determinants of FVII binding to TF. The extracellular region of TF binds tightly to FVII/FVIIa to form a highly active procoagulant complex. The extracellular region of TF is both necessary and sufficient for activity, as variants lacking either the 21-residue cytoplasmic domain or both the cytoplasmic and transmembrane domains retain full procoagulant activities [14, 15] . The substrates of the TF/FVIIa complex are FIX and FX. FVII, FIX and FX share a common protein structure; they are zymogens of vitamin K-dependent serine proteases with the domain architecture: g-carboxylated (Gla) domain, epidermal growth factor (EGF) like domain 1, EGF-like domain 2 and serine protease domain (Gla-EGF1-EGF2-SP; Fig. 1 ). The Gla domain contains a number of glutamic acid residues that are posttranslationally modified by addition of a g-carboxyl group in a vitamin-K-dependent process. It forms a Ca 2þ -dependent fold that confers affinity to negatively charged phospholipid membranes. EGF-like domains are widely dispersed in nature and are often involved in protein-protein interactions. The serine protease domain is homologous to that of chymotrypsin. Although the structural elements responsible for the trypsin fold and archetypal catalytic triad serine, histidine and aspartate are highly conserved, amino acid substitutions to surface loops that border the active site and substrate recognition pocket confer diverse functional properties to the individual proteases [16] . FVII/FVIIa interacts with the extracellular domain of TF primarily through the Gla and EGF-1 domains, although the EGF2 and serine protease domains also contact TF [12] . Similarly, Gla and EGF-1 domains of the substrates, FIX and FX, represent the primary determinants in binding to TF-FVIIa and formation of the ternary complex [17, 18] . A putative substratebinding region (S195 G196 K197 K198) [7, [19] [20] [21] , which is highly conserved ( Fig. 1 ) in TF, has been identified in binding FIX/FX through their Gla domains. The importance of Ca 2þ ions in generating the characteristic loop structure of the Gla domain is well documented; however, recently it has been shown that at physiologic concentrations of divalent cations, Mg 2þ occupies two or three of the divalent ion-binding sites in the Gla domain. These results suggest that Mg 2þ plays an important role in physiologic blood coagulation. Furthermore, residues in the TF substrate-binding region have been implicated in binding the FX Gla domain in a Mg 2þ -dependent manner [13, 22, 23] . Conversion of FVII to FVIIa is the result of a single proteolytic cleavage at the Arg212-Ile213 (nomenclature according to Goodeve et al. [4 & ], legacy numbering þ60) peptide bond producing a disulfide-linked two-chain molecule. Unlike other members of the trypsin superfamily, the neo N-terminus generated upon activation of FVII fails to insert into the activation pocket leading to a nonoptimal alignment of the catalytic machinery, rendering FVIIa 'zymogen like' with significantly reduced catalytic activity. Binding of FVIIa to TF allosterically corrects this defect, transforming FVIIa into a catalytically competent enzyme. In addition, TF ensures optimal orientation and positioning of the FVIIa catalytic domain above the membrane surface for optimal interaction with its substrates (FIX and FX), thereby enhancing the proteolytic activity by 10 6 -fold [24, 25] .
TISSUE FACTOR INITIATES BLOOD COAGULATION
Exposure of blood to cells expressing TF on their surface is both necessary and sufficient to initiate blood coagulation in vivo. FVII bound to TF is exquisitely sensitive to activation, and although many enzymes are capable of converting FVII to FVIIa, the most important one in vivo is likely FXa. However, how is this triggered if FXa is the product of TF-FVIIa? In blood, 4% of total circulating FVII is in the form of FVIIa that has little functional activity in the absence of its cofactor TF [26] . It is this pool of FVIIa that most likely serves to prime the system to respond upon exposure to TF. Activation of FVII to the protease FVIIa and formation of a highaffinity complex of TF-FVIIa result in activation of FIX and FX by the TF-FVIIa complex. A schematic of TF-initiated thrombin generation, including the important feedback reactions of thrombin, is shown in Fig. 2 .
The TF-FVIIa complex is rapidly inactivated by TF pathway inhibitor (TFPI), a Kunitz-type inhibitor released from thrombin-activated platelets or found on the surface of endothelial cells. TFPI inhibits TF-FVIIa by the formation of a quaternary-inhibited complex of TF-FVIIa-FXa-TFPI in an FXa-dependent manner ( ). The duration of the functional TF-FVIIa complex is therefore dependent on the relative concentrations of TF and TFPI, and these may vary at a particular site of vascular injury. This may help one to explain the differential bleeding phenotypes seen in different coagulation deficiencies. The sites most commonly affected by spontaneous bleeding in haemophilia A or B patients, skeletal muscle and joints, have undetectable-to-low TF expression.
Mutations in the gene encoding TF would be predicted to lead to either a bleeding (loss of function) or a prothrombotic (gain of function) phenotype; however, no congenital abnormalities have been described to date. Targeted disruption of the mouse TF gene ( f3) results in embryonic lethality of f3 À/À embryos at embryonic days 9.5-10.5 [29] [30] [31] , and therefore, loss in early pregnancy most probably accounts for the lack of TF-deficient individuals seen in clinical practice.
TISSUE FACTOR EXPRESSION
TF is constitutively expressed on extravascular cells of many tissues, such as skin, organ surfaces, vascular adventitia and epithelial-mesenchymal surfaces [32, 33] . The cellular distribution of TF at biological boundary layers led to the proposal that it functions as a 'haemostatic envelope', ensuring that following disruption of vascular integrity blood is immediately exposed to cells expressing TF, leading to the initiation of blood coagulation.
Cells within the vasculature, including endothelial cells, do not normally express TF. However, induced expression of TF in cells within the vasculature is implicated in the pathogenesis of thrombosis in atherosclerosis [34] , disseminated 
Schematic representation of the blood coagulation network initiated by exposure of flowing blood to cells expressing tissue factor. Formation of a high affinity complex of tissue factor-factor VIIa results in activation of factor IX and factor X by the tissue factor-factor VIIa complex. In the absence of its activated cofactor factor Va, factor Xa generates only trace amounts of thrombin from prothrombin. Although insufficient to initiate significant fibrin polymerization, thrombin formed in this initiation stage of coagulation is able to back-activate factor V, factor VIII and factor XI by limited proteolysis and to activate platelets providing a negatively charged surface for the assembly of procoagulant complexes. In the amplification phase of coagulation, factor XIa activates further factor IXa which forms a complex with factor VIIIa. This is the intrinsic tenase complex (factor VIIIa-IXa) that activates sufficient factor Xa to form a complex with factor Va, producing the prothrombinase complex (factor Va-Xa). This results in the explosive generation of thrombin that ultimately leads to generation of a fibrin clot.
A key feature of these processes is the assembly of multimolecular complexes on phospholipid surfaces provided by activated platelets. Each of these complexes consists of a cofactor (tissue factor, factor Va and factor VIIIa), an enzyme (factor VIIa, factor IXa and factor Xa) and a substrate that is a zymogen (factor IX, factor X and prothrombin) of a serine protease. The product of one reaction becomes the enzyme in the next complex. The cofactors factor V and factor VIII are themselves activated by limited proteolytic digestion. Positive feedback loops are represented by red dashed lines, whereas negative feedback loops by blue dashed lines. F, factor; PS, phosphatidylserine; TF, tissue factor; TFPI, TF pathway inhibitor.
intravascular coagulation [35] , malignancy [36] and hyperacute rejection of zenografts [37] . In-vitro TF expression can be induced in endothelial cells and monocytes by a variety of agonists. TF expression is primarily controlled at the transcriptional level, although posttranscriptional stabilization of TF mRNA also contributes to its rapid induction [38, 39] . The proximal promoter has been extensively studied, and cis-acting and trans-acting factors required for appropriate gene regulation in vitro have been characterized (reviewed in [40] ). Induction of TF mRNA following stimulation occurs rapidly and peaks at 2 h. TF protein levels on the cell surface peak at 4 h, and these remain high for up to 24 h. Although the response of both monocytes and endothelial cells in vitro to a variety of different agonists has been well documented and shown to be very similar, evidence for endothelial cell expression of TF in vivo is scant and remains controversial. In an experimental model of Gram-negative sepsis in baboons endothelial cell expression of TF was reported only in the splenic vasculature [41] .
More recent data using this model demonstrated immune-reactive TF in the aorta; however, this was restricted to granular structures on the surface of endothelial cells, and it could not be determined whether the TF was produced by endothelial cells or transferred to the endothelial cell surface [42] . Two studies in mice and rabbits have reported TF immunoreactivity in endothelial cells following treatment with lipopolysaccharide (LPS) but the data are open to other interpretation [43, 44] . In contrast, a number of other studies have failed to detect TF expression in endothelial cells in LPS-treated mice and rabbits [40, [45] [46] [47] . Genetic approaches to generate cell lineage-specific TF gene deletion transgenic mice have shown that TF expression in endothelial cells in vivo does not contribute to the initiation of coagulation in a mouse model of endotoxemia or carotid artery thrombosis. In contrast, in vivo induced expression of TF on monocytes/macrophages is clearly associated with disease conditions. Rupture of atherosclerotic plaques exposes a large amount of TF expressed on macrophage-derived foam cells leading to thrombosis and myocardial infarction. In endotoxemic animals and humans monocytes express TF leading to disseminated intravascular coagulation. Another controversial and complex area of interest is that of 'blood borne' extracellular TF and its role in propagation of thrombosis. Immuno-reactive TF is detectable in plasma either as a soluble protein or on circulating microparticles (also known as microvesicles or extracellular vesicles). Microparticles are defined as heterogeneous, submicron (0.1-1 mm) vesicles released from cells in response to various stimuli. They have an intact phospholipid bilayer membrane and carry membrane proteins specific to their cellular origin. However, transfer from one microparticle to another or to other cell types via specific receptor-mediated interactions or fusion may mean surface antigens do not accurately reflect their cellular origins. Under normal conditions, cells maintain a phospholipid asymmetry with negatively charged phosphatidylserine (PS) confined primarily to the inner leaflet of the plasma membrane. The collapse of this asymmetry appears critical to the formation of microparticles and therefore the majority are PS positive, as assessed by binding of fluorescently labelled annexin V or lactahedrin. The role of microparticles in many pathological conditions, including thrombosis, has been extensively studied (recently reviewed in [48] ). The contribution of microparticles to a procoagulant phenotype may arise through the provision of a negatively charged phospholipid surface to promote the assembly of the procoagulant complexes or because the microparticles are also TF positive. Microparticles positive for TF are low to undetectable in healthy individuals but increase significantly in various pathological conditions. The analysis of circulating microparticles and their procoagulant phenotype is however fraught with difficulties as preanalytical parameters can impact the outcome. These include the type of anticoagulant, phlebotomy, transport, centrifugation and freezing of blood samples. The International Society of Thrombosis and Haemostasis (ISTH) issued guidance on standardization of protocols to reduce variability in sample preparation [49] . Similarly, there are several analytical variables that can affect the detection and quantification of microparticles by flow cytometery, which is the most common method of microparticle analysis in biological samples. These include the type of flow cytometer and its ability to measure submicron particles, gating strategies and the choice of assay to detect TF. The ISTH has also established a standardized method for quantification of microparticles by flow cytometery that uses size-calibrated fluorescent beads which may help to address some of these issues [50] . Microparticle TF levels can be measured either antigenically using flow cytometry or ELISA or functionally by measuring FXa generation. In the case of antigen measurement, careful choice of appropriate antibodies is essential to ensure specific detection of total TF. For example, the inhibitory antihuman TF mAb HTF-1 completes with FVII/FVIIa for binding to TF and may not adequately detect TF-FVII complex, thereby underestimating TF levels [51] . Plasma TF concentrations have been quantified in multiple studies using the Imubind TF ELISA (Sekisui Diagnostics LLC, Lexington, Massachusetts, USA) which uses monoclonal capture and polyclonal detection antibodies; however, comparison of results obtained with other monoclonal assays suggests that the Imubind assay detects other cross-reactive proteins and may not accurately reflect plasma TF levels [52] . Activity assays offer the advantage of specificity and sensitivity as well as detecting functional TF-FVIIa activity towards its macromolecular weight substrate FX [53 & ]. However, it should be noted that antigen and activity-based assays may not correlate with each other, which may be a result of TF encryption (discussed below) rather than a technical problem with the assays.
TISSUE FACTOR ENCRYPTION
In virtually every cell type, TF exists in two forms: a latent or encrypted form that binds FVII/FVIIa but does not activate FX, and an active or deencrypted form that activates FX to FXa and is therefore procoagulant. Both forms of TF are expressed on the surface of cells and encrypted TF can be converted into a procoagulant active form in a number of experimental ways that include cell lysis, calcium ionophore treatment or LPS, thrombin or cytokoine treatment. The mechanism(s) that regulate the activity of TF are controversial. The two schools of thought will be briefly described in this review but the reader is referred to the following articles for an indepth discussion of the conflicting views [54,55 & ]. Membrane phospholipid asymmetry is actively maintained by the action of a number of molecular mechanisms involving flippases (transport PS to the inner leaflet), floppases (transport PS to the outer leaflet) and scramblase (transport PS bidirectionally). Inhibition or activation of any of these enzymes may lead to a collapse of the PS asymmetry. The phospholipid content of membranes has a significant impact on the procoagulant function of TF. Relipidation of purified TF in vesicles containing PS greatly accelerates TF procoagulant activity. One school of thought is that TF procoagulant activity is regulated by the local phospholipid microenvironment. An alternative school of thought suggests TF is encrypted in an inactive form by reduction of the disufide bond closest to the membrane (C275-C295) and activated by oxidation to form the disulfide bond. It is proposed that this thioldisulfide exchange is regulated by protein disulphide isomerase, an abundant oxido-reductase predominantly expressed in the lumen of the endoplasmic reticulum but secreted and associated with the surface of various cell types, including platelets, monocytes and macrophages. The role of the disulfide bond in TF function remains controversial and has polarized opinion.
TISSUE FACTOR SIGNALLING
As discussed above, the TF-FVIIa complex catalyses the activation of FIX and FX leading to thrombin generation and subsequently formation of a fibrin clot. Over the last 20 years, it has become clear that activated coagulation proteases play an important role in cellular signalling independent of fibrin generation. This occurs through activation of protease-activated receptors (PARs), a subfamily of seven-transmembrane G-protein-coupled receptors. There are four members of the PAR family (PAR-1, PAR-2, PAR-3 and PAR-4) encoded by the their respective genes (F2R, F2LR1, F2RL2 and F2RL3). Their unique mechanism of activation involves specific enzymatic cleavage of the PAR extracellular domain, generating a neo-amino terminus that functions as a 'tethered ligand' by binding intramolecularly and generating an intracellular signal through G-proteins leading to phosphatidylinositol hydrolysis, Ca 2þ transients and activation of intracellular kinases. Vitamin K-dependent coagulation factors with the exception of FIXa are able to selectively activate cell surface PARs. Thrombin can directly activate PAR-1, PAR-3 and PAR-4 but not PAR-2; however, PAR-2 can be trans-activated by thrombin-activated PAR-1 when the N-terminal PAR-1 tethered ligand is able to interact with the binding pocket of an adjacent PAR-2 receptor. Although thrombin can activate both PAR-1 and PAR-4, markedly higher concentrations of thrombin are required to activate PAR-4. FXa can directly activate both PAR-1 and PAR-2 as well as through the ternary TF-FVIIa-FXa complex, whereas the TF-FVIIa complex can only activate PAR-2. The PARs activation has been shown to elicit intracellular signalling that results in a plethora of cellular responses including proliferation, migration, cell shape change, secretion of cytokines/chemoattractants, degranulation as well as the initiation of various transcriptional responses. It has become clear that coagulation protease activation of PARs plays an important role in normal haemostasis, vascular development, inflammation in a variety of disease models, cancer biology as well as fibrosis seen in a number of pathological situations across all major organ systems [56 & ]. Coagulation protease signalling through PARs is complex. PARs are expressed on a variety of different cell types in a cell-type specific manner; however, the same cell type isolated from different sources may display different expression patterns of PARs. For example, primary fibroblasts of a different origin (dermal vs lung) show distinct PAR expression profiles and respond differently to FXa stimulation in vitro [57] . Similarly, endothelial cells from different origins have been shown to respond differently to PAR agonist peptides suggesting differential PAR expression [58] . Furthermore, although following tissue injury cells may be exposed to blood containing FVII/FVIIa, FX and prothrombin, in the absence of tissue damage the source of coagulation factors may be local and may not reflect the makeup or concentrations found in plasma and therefore protease-specific responses may occur [59] [60] [61] [62] . Initially, because TF-FVIIa and FXa ultimately lead to the generation of thrombin and PAR-1 signalling, the significance of the other protease complexes in activating PARs and initiating cellular responses was largely overlooked. However, the recognition that PAR-2 signalling plays a key role in a number of pathological responses has reignited interest in FXa as an important mediator of inflammatory responses [63] .
ALTERNATIVELY SPLICED TISSUE FACTOR
The current review has concentrated on the expression and function of full-length TF; however, another isoform of TF generated by alternative splicing of the TF transcript has been described [64] . The alternatively spliced TF mRNA transcript lacks exon 5 which results in a translation product (AS-TF) of 206 amino acids that shares the first 166 amino acids with full-length TF but lacks three of the b-strands (E, F and G) that comprise the C-terminal
(a) Sequence alignment of predicted amino acid sequences encoding full-length tissue factor and alternatively spliced tissue factor. The amino acid sequence in common is shaded black. The transmembrane domain sequence is shaded grey. Disulfide bonds are indicated by square brackets. Molecular model of the extracellular domain of tissue factor (Protein Databank: 1DAN). The tissue factor protein chain is represented by a green ribbon with residues conserved in all species analysed shown in blue. (b) Represents full-length tissue factor and (c) represents alternatively spliced tissue factor demonstrating the loss of three of the b-strands that comprise the C-terminal immunoglobulin like domain.
Tissue factor pathway in haemostasis and beyond McVey immunoglobulin-like domain which includes the disulfide bridge C275-C295 (Fig. 3 ). In addition, AS-TF also lacks the transmembrane and cytoplasmic domains and is, therefore, a soluble protein with a unique 40 amino acid C-terminus (Fig. 3) . The unique neo-C-terminus does not appear to be highly conserved as protein database searches fail to identify TF sequences with sequence identity with the exception of some primate sequences. The mouse AS-TF mRNA has been cloned [65] , and the sequence of the C-terminal region shares limited amino acid identity (18/40) and is an additional 53 amino acids longer. The expression pattern of AS-TF essentially mirrors that of full-length TF but it is expressed at significantly lower levels. Perhaps not surprisingly given its structure AS-TF has no procoagulant activity. However, AS-TF has been associated with increased cancer cell migration, invasion, metastasis and proliferation. The effect of AS-TF appears to be mediated through direct interaction with integrins (avb3 and a6b1), leading to activation of cell signalling and subsequent modulation of cancer cell biology [66,67 & ,68] . In contrast to fulllength TF, the biological actions of AS-TF appear to be independent of PAR signalling.
CONCLUSION
TF is a cellular receptor that plays a pivotal role in regulating the initiation of blood coagulation and wound repair processes. Despite many decades of research that have increased our understanding of the structure and function of this molecule, there still remains much to learn about its role in the pathophysiology of disease.
